News

Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial...

read more

Personalized Health Technologies Conference 2024

  You can now submit your abstracts for contributed talks, posters, and workshops. The fourth edition of the conference will be held on August 27th and 28th, 2024 at ETH Zurich. It will bring together experts from a variety of disciplines to explore present and future directions in the field of personalized health technologies and...

read more

Inauguration of CUTISS Innovation

The CUTISS team is proud to announce the recent inauguration of CUTISS Innovation, the French subsidiary of CUTISS AG, at the renowned Sophia Antipolis technology park in France. CUTISS Innovation is supporting and extending our R&D activities in regenerative medicine, including skin pigmentation, aging and healing. The Provence-Alpes-Côte d’Azur region is...

read more

InSphero launches new website showcasing “The Model of Excellence™” empowering breakthroughs in 3D in vitro therapies

Zurich, Switzerland – October 17, 2023 InSphero AG, a global leader in 3D in vitro technologies, is thrilled to announce the launch of its brand-new website, designed to provide researchers with enhanced usability and an array of resources for cutting-edge advancements in Liver Safety, Liver Disease, Oncology & Immunology, and Islet Biology. The website...

read more